ABSTRACT
INTRODUCTION
Fetal macrosomia is associated with adverse perinatal outcome 1, 2 . For the mother, this includes an increased incidence of emergency Cesarean section, operative vaginal delivery, anal sphincter injury, and postpartum hemorrhage 3 -8 . The macrosomic neonate is at increased risk of shoulder dystocia, brachial plexus injury, fracture of the clavicle or humerus, birth asphyxia, stillbirth and increased peripartum mortality 3 -6,9-12 . Long-term complications for the neonate include increased risk of obesity, Type 2 diabetes mellitus and asthma 2,13 -15 . The definition of macrosomia varies between studies, but there is consistency in the trend that the higher the birth weight the greater the risk of adverse outcome. The majority of the associated harm to both mother and neonate is due to traumatic vaginal delivery. Elective delivery by Cesarean section or early induction of labor in suspected macrosomia should reduce this harm. Unfortunately, previous studies and guidelines assessing the effectiveness of elective delivery for a suspected macrosomic fetus are hampered by the poor performance of current models to predict macrosomia 16 -18 . An accurate model that could predict prospectively which pregnancies are at risk of delivering a large-for-gestational-age (LGA) baby would be useful in counseling women on the risks surrounding attempted vaginal delivery as well as providing the basis for future research on timing of delivery in cases of suspected LGA. The aim of this study was to develop such a model that combined maternal history, fetal biometry and maternal biophysical and biochemical markers.
METHODS
The data for this study were derived from prospective screening for adverse obstetric outcomes in women attending their routine hospital visit in the first, second and/or third trimester of pregnancy at King We examined 76 300 singleton pregnancies at 11 + 0 to 13 + 6 weeks' gestation, 54 999 at 19 + 0 to 24 + 6 weeks, 25 727 at 30 + 0 to 34 + 6 weeks and 6181 at 35 + 0 to 37 + 6 weeks. The first-trimester dataset was used to derive the prior risk, based on maternal factors, and all datasets were used to investigate the potential value of combined screening by maternal factors and biophysical or biochemical markers in the three trimesters of pregnancy. In all three trimesters we measured uterine artery pulsatility index (UtA-PI) 19 and obtained maternal blood samples for measurement of serum biochemical markers. In the second and third trimesters, we estimated fetal weight from measurements of fetal head circumference (HC), abdominal circumference (AC) and femur length (FL) 20 . Gestational age was determined from the measurement of fetal crown-rump length (CRL) at 11-13 weeks or the fetal HC at 19-24 weeks 20, 21 . The pregnancies included in the study all resulted in the live birth or stillbirth of phenotypically normal babies, delivered at or after 24 weeks' gestation. Written informed consent was obtained from the women agreeing to participate in the study, which was approved by the National Health Service research ethics committee.
Maternal history and characteristics
Patient characteristics that were recorded included maternal age, racial origin (Caucasian, Afro-Caribbean, South Asian, East Asian and mixed), method of conception (spontaneous/assisted conception requiring the use of ovulation drugs/in-vitro fertilization), cigarette smoking during pregnancy (yes/no), medical history including diabetes mellitus Type 1 or 2, family history of diabetes mellitus (first-, second-or third-degree relative with diabetes mellitus Type 1 or 2), obstetric history including parity (parous/nulliparous if no previous pregnancies ≥ 24 weeks' gestation), previous pregnancy with gestational diabetes (GDM), neonatal birth-weight Z-score (corrected for gestational age at delivery 22 ) of previous pregnancy and the time interval between the last delivery and conception of the current pregnancy in years. The maternal weight and height were also measured. At the 30-34 and 35-37-week visits, the diagnosis of GDM in the index pregnancy was recorded.
Outcome measures
Details of maternal characteristics, medical and obstetric history and the findings of the assessments at 11-13, 19-24, 30-34 and 35-37 weeks were recorded in our secured database. Data on pregnancy outcome were obtained from the maternity computerized records or the general medical practitioners of the women and were also recorded in our secured database. The primary outcome of the study was delivery of a LGA neonate. The newborn was considered to be LGA if the birth weight was > 95 th percentile (LGA > 95 th ) after correcting for gestational age at delivery 22 .
Statistical analysis
The a-priori risk for LGA > 95 th was calculated using multivariable logistic regression analysis with backward stepwise elimination to determine which maternal factors had significant contribution to LGA > 95 th . The observed measurements of biomarkers were log 10 transformed to make their distributions Gaussian. Each measured value in the outcome groups was expressed as a multiple of the normal median (MoM) after adjustment for those characteristics found to provide a substantial contribution to the log 10 transformed value 23 -26 . The observed measurements of fetal nuchal translucency thickness (NT) were expressed as delta values corrected for gestational age 27 . The observed measurements of HC, AC and FL were expressed as Z-scores, corrected for gestational age 22 . Mann-Whitney U-test was used to compare the biometric Z-scores and biomarkers between the outcome groups. Regression analysis was used to determine the significance of association between the log 10 MoM values of biomarkers.
Multivariable logistic regression analysis was used to determine if the maternal factor-derived logit (a-priori risk), fetal biometry and biomarkers had significant contribution in predicting LGA > 95 th . The performance of screening was determined by receiver-operating characteristics (ROC) curves. Similarly, the algorithm was used to determine the performance of screening for LGA defined by birth weight > 90 th percentile (LGA > 90 th ) and > 97 th percentile (LGA > 97 th ) and birth weight > 4000 g (LGA > 4000 g) and > 4500 g (LGA > 4500 g).
The statistical software package SPSS 22.0 (SPSS Inc., Chicago, IL, USA) and Medcalc (Medcalc Software, Mariakerke, Belgium) were used for data analyses.
RESULTS
Maternal and pregnancy characteristics of the study populations examined at 11-13, 19-24, 30-34 and 35-37 weeks' gestation are presented in Table S1 . The Pearson correlations between each of the biomarkers assessed at different stages in pregnancy in LGA > 95 th and those without LGA are demonstrated in Tables S2-S5 .
Large-for-gestational age

Prior risk
The a-priori risk for LGA > 95 th is calculated from the following formula: odds/(1 + odds), where odds = e Y and Y is derived from multivariable logistic regression analysis. Regression coefficients and adjusted odds ratios of each of the maternal factors in the prediction algorithms are presented in Table 1 (R 2 = 0.174, P < 0.0001). The likelihood of LGA > 95 th increased with increasing maternal weight and height. In parous women, the risk increased with neonatal birth weight Z-score in previous pregnancy and decreased with interpregnancy interval and was higher in women with a previous history of gestational diabetes. The risk was higher in women with pre-existing diabetes mellitus Type 1 and lower in women of Afro-Caribbean and South Asian racial origins, in cigarette smokers, in nulliparous women and in women with chronic hypertension. The likelihood of LGA > 95 th was not altered significantly by maternal age (P = 0.128), method of conception (P = 0.337), personal history of systemic lupus erythematosus/antiphospholipid syndrome (P = 0.813) or family history of diabetes mellitus (P = 0.692).
Performance of screening for LGA > 95 th with modifiable maternal risk factors, such as pre-existing diabetes, increased body mass index, previous pregnancy with LGA neonate and previous or current gestational diabetes, that were treated as an individual screening test is demonstrated in Table 2 .
11-13-week combined test
At 11-13 weeks, the delta NT, and MoM values for pregnancy-associated plasma protein-A (PAPP-A), free beta-human chorionic gonadotropin (β-hCG) and placental growth factor (PlGF) were significantly higher and UtA-PI MoM was significantly lower (P < 0.0001; Table S6 ) in the LGA > 95 th group compared to the non-LGA group. Multivariable logistic regression analyses demonstrated that, in the prediction of LGA > 95 th , there were significant independent contributions from maternal factors and combinations of delta NT, log 10 MoM values of PAPP-A, free β-hCG and UtA-PI (Table S7) , however PlGF MoM did not contribute significantly to this prediction (P = 0.063).
Screening by maternal factors at 11-13 weeks predicted 38.3%, 43.6%, 46.8%, 32.0% and 43.9% of LGA > 90 th , LGA > 95 th , LGA > 97 th , LGA > 4000 g and LGA > 4500 g, respectively, at a false-positive rate (FPR) of 10%. The respective detection rates for combined screening with maternal factors, delta NT, PAPP-A, free β-hCG and UtA-PI were 39.8%, 45.8%, 49.2%, 33.6% and 47.7% (Figure 1 , Table S8 and Table 3 ).
19-24-week combined test
At 19-24 weeks, all Z-scores of fetal biometric measurements and MoM values for PAPP-A, free β-hCG, PlGF and sFlt-1 were significantly higher and UtA-PI MoM was significantly lower (P < 0.0001; Tables S6 and S9) in the LGA > 95 th group compared to the non-LGA group. At 19-24 weeks, multivariable logistic regression analyses demonstrated that, in the prediction of LGA > 95 th , there were significant independent contributions from maternal factors, fetal biometry and combinations of log 10 MoM values of PAPP-A and UtA-PI (Table S10) , however maternal serum free β-hCG (P = 0.058), PlGF (P = 0.469) and sFlt-1 (P = 0.592) did not contribute significantly to this prediction.
Combined screening by maternal factors and fetal biometry at 19-24 weeks predicted 43.9%, 50.5%, 54.3%, 36.0% and 52.2% of LGA > 90 th , LGA > 95 th , LGA > 97 th , LGA > 4000 g and LGA > 4500 g, respectively, at a FPR of 10%. The respective detection rates for combined screening with maternal factors, fetal biometry, maternal serum PAPP-A and UtA-PI were 45.7%, 53.7%, 55.9%, 40.6% and 57.3% (Figure 2 , Table S11 and Table 3 ).
30-34-week combined test
At 30-34 weeks, all Z-scores of fetal biometric measurements and MoM values for PAPP-A, PlGF and sFlt-1 were significantly higher and UtA-PI MoM was significantly lower (P < 0.0001; Table S6 and S9) in the LGA > 95 th group compared to the non-LGA group; free β-hCG MoM was not significantly different between outcome groups. At 30-34 weeks, multivariable logistic regression analyses demonstrated that, in the prediction of LGA > 95 th , there were significant independent contributions from maternal factors, fetal biometry and combinations of log 10 MoM values of PlGF and UtA-PI (Table S12) , however a diagnosis of GDM in the index pregnancy (P = 0.846), maternal serum PAPP-A (P = 0.469) and sFlt-1 (P = 0.131) did not contribute significantly to this prediction.
Combined screening by maternal factors and fetal biometry at [30] [31] [32] [33] [34] LGA > 4000 g and LGA > 4500 g, respectively, at a FPR of 10%. The respective detection rates for Table 3 Performance of screening for large-for-gestational-age neonates with birth weight > 95 th percentile by a combination of maternal characteristics, medical and obstetric history, fetal biometry and biomarkers β-hCG, free β-human chorionic gonadotropin; DR, detection rate; FPR, false-positive rate; NT, nuchal translucency; PAPP-A, pregnancyassociated plasma protein-A; PlGF, placental growth factor; UtA-PI, uterine artery pulsatility index.
DR (95% CI)(%) for fixed FPR FPR (95% CI)(%) for fixed DR
combined screening with maternal factors, fetal biometry, maternal serum PlGF and UtA-PI were 57.0%, 67.0%, 70.9%, 46.9% and 71.4% (Figure 3 , Table S13 and  Table 3 ).
35-37-week combined test
At 35-37 weeks, all Z-scores of fetal biometric measurements and PlGF MoM were significantly higher and UtA-PI MoM was significantly lower (P < 0.0001; Table S6 and S9) in the LGA > 95 th group compared to the non-LGA group; sFlt-1 MoM was not significantly different between outcome groups. At 35-37 weeks, multivariable logistic regression analyses demonstrated that in the prediction of LGA > 95 th there were significant independent contributions from maternal factors, fetal biometry and log 10 MoM PlGF (Table S14) , however a diagnosis of GDM in the index pregnancy (P = 0.100), maternal serum sFlt-1 (P = 0.173) and UtA-PI (P = 0.231) did not contribute significantly to this prediction.
Combined screening by maternal factors and fetal biometry at [35] [36] [37] (Figure 4 , Table S15 and Table 3 ).
DISCUSSION
Main findings of the study
This screening study for LGA neonates in a large unselected population of pregnant women attending for routine scans has demonstrated that the risk for delivering LGA neonates can be predicted from combined screening with maternal factors and fetal biometry at 19-24, 30-34 and 35-37 weeks' gestation.
The model on maternal factors demonstrated that the risk for delivering LGA neonates is higher in parous women with previous GDM and in women with a medical history of Type 1 diabetes mellitus. The risk is lower in women of Afro-Caribbean and South Asian racial origin than in Caucasian women, in cigarette smokers than in non-smokers, in nulliparous women than in parous women without previous GDM, and in those with a medical history of chronic hypertension. The risk increases with increasing maternal weight and height, and, in parous women, the risk increases with neonatal birth weight in previous pregnancy and decreases with interpregnancy interval. The findings of this study confirm that, in pregnancies that deliver LGA neonates, fetal biometric measurements at 19-24, 30-34 and 35-37 weeks are increased, and maternal serum metabolites of placental function are increased and UtA-PI is decreased across all trimesters. In addition, fetal NT at 11-13 weeks is increased. However, addition of biomarkers does not improve the performance of screening beyond that obtained by maternal factors and fetal biometry in the second and third trimesters. The performance of the combined test was best at 35-37 weeks, when the detection rate was 73% at a 10% FPR, rather than at 19-24 weeks (51%) or 30-34 weeks (65%).
Comparison with findings from previous studies
The risk factors for LGA incorporated in our new model have been reported in previous studies 3, 7, 8, 28 -40 . In our study, continuous variables were treated as such and the risk factors were combined through multivariable logistic analysis that attributes the appropriate importance to each factor and takes into account their possible inter-relations. This approach is an essential first step in the use of a combination of maternal factors with fetal biometry for the continuing development of more effective methods of screening for LGA. A systematic review of 20 ultrasound studies on the prediction of birth weight > 4000 g highlighted the great heterogeneity between the studies, in terms of gestational age at investigation which ranged from 28 to ≥ 41 weeks, number of cases examined which ranged from 74 to 1690, prior risk of study populations and fetal measurements recorded; the reported detection rates ranged from 12% to 75% and FPRs ranged from 1% to 32% 41 . Several recent studies have also reported the use of ultrasound-derived estimated fetal weight (EFW) in the third trimester for prediction of delivery of LGA neonates. Kayem et al. examined 1689 pregnancies within 8 days of delivery after 37 weeks; the detection rate of birth weight > 4000 g, from EFW derived from the fetal AC, was 54% at a FPR of 5% 42 . Pilalis et al. examined 2308 pregnancies and reported that the detection rate of LGA > 95 th percentile was 31% at a 10% FPR from a combination of maternal weight, height, fetal CRL and delta NT at 11-13 weeks' gestation and this increased to 52% with the addition of fetal biometry at 30-32 weeks 43 . The same group evaluated screening for LGA > 95 th at two different points in the third trimester, with 3690 pregnancies assessed at 30-34 weeks and 2288 at 34-37 weeks; they reported that the detection rate from screening with EFW alone was 53% at 30-34 weeks, at a 10% FPR, and this improved to 63% at 34-37 weeks 44 . In our study of combined screening with maternal factors and fetal biometry, the detection rate of LGA > 95 th was 65% at 30-34 weeks and 73% at 35-37 weeks, at a 10% FPR.
Implications for clinical practice
In the proposed new pyramid of pregnancy care 45 , first-trimester identification of pregnancies at high risk for subsequent delivery of LGA neonates has the potential to reduce the prevalence of LGA through restriction of maternal weight gain during pregnancy. However, recent randomized studies have reported that, certainly in obese pregnant women, measures such as lifestyle intervention or administration of metformin does not reduce maternal weight gain or the rate of fetal macrosomia 46, 47 . The extent to which alternative strategies prove to be beneficial will be the subject of future investigations.
The value of identifying pregnancies with LGA fetuses in the third trimester of pregnancy relates to the potential of reducing macrosomia-related adverse events during labor and delivery. This harm can only be reduced by appropriate intervention. A randomized trial reported that clinically significant shoulder dystocia could be reduced through early term induction of labor in cases of suspected macrosomia 48 . Campbell suggested that pregnancies identified as being LGA at a routine scan at 30-34 weeks' gestation should have a diagnostic scan at 39 weeks and, if EFW is > 4500 g, women should be offered elective Cesarean section 1 . Based on the findings from our study, we believe that the timing of screening for LGA should be at 35-37 weeks, rather than at 30-34 weeks. Counseling women identified as high risk for a LGA fetus will remain problematic until more definitive intervention studies are performed.
Our study provides the basis for identifying high-risk pregnancies that would be the subject of future intervention studies. We found that a combination of maternal factors and fetal biometry at 36 weeks' gestation could identify about 75% of pregnancies with macrosomic fetuses, at a 10% FPR.
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RESUMEN
Objetivo Desarrollar un modelo, basado en las características maternas y la historia médica (factores maternos), con el objetivo de predecir el parto de recién nacidos grandes para la edad gestacional (GEG), valorar el potencial de las biometrías y los biomarcadores del feto en el primer, segundo y tercer trimestre como parámetros que contribuyan a mejorar dicho modelo.
Métodos Este fue un estudio de cribado de 76 300, 54 999, 25 727 y 6181 embarazosúnicos entre las semanas de gestación 11-13, 19-24, 30-34 y 35-37, respectivamente. El riesgo a priori de neonatos GEG con un peso al nacer > percentil 95 (GEG > p95) se calculó por medio de un análisis de regresión logística multivariable para determinar cuales factores maternos tuvieron una contribución significativa. A continuación se empleó un análisis de regresión para determinar si el cribado mediante una combinación de factores maternos, biometría fetal y una serie de marcadores bioquímicos y biofísicos contribuyó significativamente en la predicción del parto de recién nacidos GEG.
Resultados La probabilidad de GEG > p95 aumentó con el incremento del peso y la altura maternos, y fue menor en mujeres de origenétnico afrocaribeño y de Asia del Sur, en gestantes con hábito tabáquico y en nulíparas. Se encontró un mayor riesgo en mujeres con diabetes mellitus tipo 1 preexistente y menor en aquellas con hipertensión crónica. En mujeres no nulíparas, el riesgo aumentó en aquellas en cuyo embarazo anterior se obtuvo recién nacido en Z-score y con historia previa de diabetes gestacional, y disminuyó con el intervalo entre embarazos. El cribado mediante factores maternos entre las semanas 11-13 predijo un 32%, 44% y 60% de GEG > 95, con tasas de falsos positivos (TFP) del 5%, 10% y 20%, respectivamente. Con la incorporación de la biometría fetal al modelo, las tasas de detección mejoraron hasta el 37%, 51% y 68% para las semanas 19-24, el 50%, 65% y 81% para las semanas 30-34 y el 60%, 73% y 85% para las semanas 35-37, con TFP del 5%, 10% y 20%, respectivamente. La incorporación de biomarcadores no mejoró las tasas de detección logradas el cribado mediante una combinación de factores maternos y biometría fetal.
Conclusión El cribado mediante una combinación de factores maternos y biometría fetal puede predecir una alta proporción de embarazos que conllevarán recién nacidos GEG.
